United Capital Financial Advisors LLC Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

United Capital Financial Advisors LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 360,205 shares of the company's stock after selling 60,672 shares during the quarter. United Capital Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $30,985,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S in the fourth quarter worth $86,000. Finally, Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth $4,066,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday. They set an "underperform" rating on the stock. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Tuesday. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Price Performance

NVO traded down $4.89 during midday trading on Friday, hitting $57.99. 32,192,935 shares of the company traded hands, compared to its average volume of 5,963,203. The business has a 50 day simple moving average of $76.03 and a two-hundred day simple moving average of $92.13. The company has a market capitalization of $260.23 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52-week low of $57.28 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.